- Home
- CRVS vs EYPT Comparison
CRVS vs EYPT Comparison
Compare CRVS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- EYPT
- Stock Information
- Founded
- CRVS 2014
- EYPT 1987
- Country
- CRVS United States
- EYPT United States
- Employees
- CRVS N/A
- EYPT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CRVS Health Care
- EYPT Industrials
- Exchange
- CRVS Nasdaq
- EYPT Nasdaq
- Market Cap
- CRVS 451.0M
- EYPT 439.4M
- IPO Year
- CRVS 2016
- EYPT 2005
- Fundamental
- Price
- CRVS $8.94
- EYPT $8.35
- Analyst Decision
- CRVS Buy
- EYPT Strong Buy
- Analyst Count
- CRVS 4
- EYPT 8
- Target Price
- CRVS $12.83
- EYPT $27.29
- AVG Volume (30 Days)
- CRVS 1.0M
- EYPT 1.3M
- Earning Date
- CRVS 11-12-2024
- EYPT 11-07-2024
- Dividend Yield
- CRVS N/A
- EYPT N/A
- EPS Growth
- CRVS N/A
- EYPT N/A
- EPS
- CRVS N/A
- EYPT N/A
- Revenue
- CRVS N/A
- EYPT $45,713,000.00
- Revenue This Year
- CRVS N/A
- EYPT N/A
- Revenue Next Year
- CRVS N/A
- EYPT N/A
- P/E Ratio
- CRVS N/A
- EYPT N/A
- Revenue Growth
- CRVS N/A
- EYPT 7.50
- 52 Week Low
- CRVS $1.30
- EYPT $5.87
- 52 Week High
- CRVS $10.00
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- CRVS 60.34
- EYPT 35.82
- Support Level
- CRVS $8.02
- EYPT $8.25
- Resistance Level
- CRVS $8.71
- EYPT $9.40
- Average True Range (ATR)
- CRVS 0.86
- EYPT 0.81
- MACD
- CRVS -0.17
- EYPT -0.43
- Stochastic Oscillator
- CRVS 52.25
- EYPT 2.35
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.